Our BsAbs presented potent dose-dependent ADCC activity against CD47+/CD38+ Raji and NCI-H929 cells but negligible ADCC activity against CD47+/CD38– HL-60 cells, indicating low off-tumor toxicity. This evidence concerns the gene CD38 and neoplasm.